# A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Source: https://onco.cc/trials/nct04914598/  
OnCo record `nct04914598` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cisplatin in advanced solid tumours, run by Jiangsu Simcere Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions is a phase 3 interventional study registered as NCT04914598 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 290 participants enrolled, started 2021-07-28 and due to reach its primary completion in 2025-02-10. Interventions recorded: ENDOSTAR，cisplatin and Placebo , cisplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04914598
- Phase: 3
- Setting: A Randomized, Controlled, Double-blind, Multi-center Phase Ⅲ Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
- Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Enrolled: 290

## Sources

- ClinicalTrials.gov NCT04914598: https://clinicaltrials.gov/study/NCT04914598

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/)
- companies: [Simcere Pharmaceutical](https://onco.cc/companies/simcere/)

---
JSON: https://onco.cc/api/v1/entities/nct04914598.json